In the earlier post, the pre-grant objections to the Valganciclovir application of Roche were discussed (which had some really earthy and practical comments on interpretation of s.8 of the Patents Act, notably by Indian Patent Agent). According to news reports and updates by Lawyers Collective, the Supreme Court has ordered Roche not to pursue the patent infringement case against Cipla until such time the post-grant oppositions against the patent have been disposed off. The Court has asked the Controller to

In quite a few posts earlier, both Mr.Basheer and Prashant have discussed the developments in the proceeding concerning the pre-grant opposition of Roche’s patent application for its anti-retroviral drug Valganciclovir, better known as Valcyte. In a brilliant post earlier, Prashant had discussed in sufficient detail the ruling of the Madras High Court that the petitioner NGOs were entitled to a hearing in the pre-grant opposition under s.25(1) and Rule 55 of the Patents Act. This post focuses on the grounds